Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

NCT02270983 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

254

Enrollment

INDUSTRY

Sponsor class

Conditions

Opioid-Induced Constipation

Interventions

DRUG: Linaclotide 145 micrograms
DRUG: Linaclotide 290 micrograms
DRUG: Placebo

Sponsor

Forest Laboratories

Collaborators

[object Object]